Xarelto (Rivaroxaban)

Xarelto

Approved by the FDA in 2011, Xarelto is used to reduce the risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and blood clots. Manufacturers Bayer and Janssen promote the drug has the gold standard for anticoagulants. However, it may be more dangerous than other medications on the market since there is no antidote.

No Way to Stop Xarelto’s Bleeding

By stopping the blood from clotting, blood-thinners can prevent blood clots in people suffering from conditions such as atrial fibrillation. Due to the risk of unstoppable bleeding, researchers developed an “antidote” to stop this effect in the case of emergency in users of warfarin, the most popular anticoagulant for decades.

Xarelto users aren’t so lucky. There is no antidote to reverse the anti-clotting effect of Xarelto in an emergency. This means doctors and surgeons may have limited options. It means that what could be a treatable injury for most people can be a fatal one for Xarelto users. Additionally,  unlike other anticoagulants, Xarelto doesn’t push regular blood monitoring. With regular blood monitoring, doctors can adjust the dosage to ensure patients aren’t at risk.

Xarelto Risks

Some of the potentially fatal conditions Xarelto users have suffered include:

  • Gastrointestinal bleeding
  • Brain hemorrhaging
  • Kidney bleeding
  • Rectal bleeding
  • Another internal bleeding event

Many Xarelto Deaths

Despite its short time on the market, Xarelto may already be responsible for hundreds of patient deaths. The FDA has linked Xarelto to:

  • 2,081 serious complications in 2012
  • 680 complications in the first quarter of 2013
  • 1,121 deaths reported to the FDA

Media reports also indicate that Xarelto may also be involved in 130 deaths in Germany.

ISMP 2015 Study on Rivaroxaban

Institute For Safe Medication Practices (ISMP) examined all the adverse events submitted to the FDA after patients took Xarelto. They also examined all the adverse events reported to the FDA after patients took the coagulant. Then, they determined that Xarelto failed to prevent pulmonary embolism, caused uncontrollable bleeding, and wasn’t very efficient.

They also determined that:

  • There were 1,121 patient deaths
  • 10,674 reported fatal, disabling or serious injuries
  • 9% involved bleeding cases
  • 9% embolic thrombotic or blood clot events

Xarelto As Effective As Aspirin

In October 2017, Bayer and Janssen stopped phase III of the NAVIGATE ESUS study early, when researchers showed the drug did not prevent stroke or increased bleeding better than over the counter aspirin. This screams an attempt by the manufacturers trying to get FDA approval for another use for the medication. Bayer and Janssen are trying to regain control of the anticoagulant market. They don’t care if more people have uncontrollable bleeding events from their medication in the process.

Xarelto Loses Lead and Consumers Suffer

Xarelto was a huge financial success. It made $642 million in the US in the second quarter of this year alone, but it used to dominate the anticoagulant market.  Now, another equally dangerous anticoagulant, Eliquis has edged out the medication from being in the top spot.

This pushed Bayer and Janssen to try to get more people to try the dangerous medication. In 2011, the FDA approved the medication to help deep vein thrombosis (DVT) in patients undergoing knee or hip replacement surgery.  Since then, the FDA approved Xarelto for several other reasons such as the general treatment of DVT in adults.

Now, the manufacturers set their eyes on stroke victims. The NAVIGATE ESUS trial included 7,214 patients from 31 countries. Researchers randomly gave patients once daily either 15 mg of rivaroxaban or 100 mg of aspirin. There was not a difference in stroke prevention from those taking either Xarelto or aspirin.This study was a failed attempt to push the hazardous drug on a new group of people. It is unclear if the manufactures will continue the study at a later date. An Eliquis study of the same nature is set to complete in December 2018.

Dangerous Drug Interactions

According to a paper published in the Journal of American Medical Association (JAMA), researchers from Taiwan analyzed data on 91,000 patients who were using anticoagulants, including Xarelto, Eliquis, and Pradaxa, either alone or with other medications. Their findings indicated that patients who took the anti-fungal medication Diflucan in combination with Xarelto were 25% more likely to suffer a major bleeding event.

Xarelto is a dangerous medication that continues to become even more dangerous as we learn different medication combinations. When will the FDA take a stand a recall this harmful drug?

Xarelto Recall

As of October 2017, the FDA has not recalled Xarelto despite its potential to cause harm. In 2011, some FDA scientists did not even want to approve the drug in the first place. They felt patients were at a greater risk of stroke or bleeding when using Xarelto than the trusted warfarin.  In one Xarelto clinical trial, 30 days after the study ended Xarelto subjects had experienced 22 strokes while warfarin users had experienced just six.

Xarelto Lawsuit

Thousands of patients are speaking out against Xarelto. They decided to take a stand and ask for compensation from the manufacturers Bayer and Janssen. They feel these companies are profiting on their pains and their loved ones’ deaths. The drug is dangerous because the administration can be difficult, and it can complicate the healing of wounds. There is a tiny window of time between a safe Xarelto dose and a dangerous one. Overdose or not enough of the medication is a grim reality.

Xarelto lawsuits are similar to lawsuits over Pradaxa, another newer-generation anticoagulant. Michael Brady Lynch, the founder of The Michael Brady Lynch Firm is leading the country in Pradaxa lawsuits. Michael was a member of the Plaintiff’s Steering Committee in the Pradaxa Multi-District Litigation and was instrumental in securing the $650 million settlement for those injured by Pradaxa’s uncontrollable bleeding. Mr. Lynch continues to be a leader in Pradaxa litigation nationwide in representing those who continue to suffer uncontrollable bleeding events from Pradaxa.

Attorney Lynch has said, “The U.S. numbers for Pradaxa bleeding events are truly staggering. It is on the verge of a national health disaster.”

Speak to an Attorney Today

If you or a loved one has been harmed by Xarelto, you need an attorney with experience helping people who have been harmed by pharmaceutical drugs. The attorneys at the Michael Brady Lynch Firm know what it takes to go up against drug manufacturers to get clients what they need.

How We Can Help

When you experience side effects from a dangerous drug, it can have devastating effects on your entire life. You may be entitled to compensation for their injuries and damages. The types of losses that can be recovered include:

  • Past and future medical expensesinvokana-sad
  • Lost wages
  • Loss of an ability to work; and
  • Pain and suffering

If a person dies from complications from a drug, family members may be able to recover damages for the wrongful death of their loved one, including:

  • Funeral expenses
  • Medical expenses prior to death
  • Loss of economic support; and
  • Loss of companionship

If the conduct of a drug company in manufacturing and selling drug is found to be highly reckless, punitive damages may be awarded to punish the company and deter similar conduct in the future. If you had a bleeding event after taking Xarelto, please speak to us to learn more about your rights.

Case evaluations are free of cost and without obligation. Call us today at (877) 513-9517 or contact us online to speak with an attorney about your options. We may be able to get you the help you need.

Learn More

Xarelto Even More Dangerous When Combined with Other Medications

Xarelto No More Effective Than Ordinary Aspirin

Xarelto vs Pradaxa

Judge Rules Bayer Could Have Changed Xarelto Label

Xarelto & Pradaxa Manufacturers Spent Millions Bribing Doctors

Many Receiving Xarelto Overdose

Second Xarelto Bellwether Trial Underway

New Study Suggests Xarelto Causes More Bleeding Than Even Pradaxa

Xarelto Trial Update: Week One Recap

Xarelto Bellwether Trial Begins in New Orleans

Attorney Michael Brady Lynch Lecturers on Pradaxa, Xarelto and Eliquis Litigations

Xarelto May Cause Dementia in AFib Patients

Manufacturers Testing Xarelto for 10 Additional Uses

Xarelto Cases Heading to Trial

Xarelto Approval Trial Skewed by Faulty Blood Monitor

Corporate Greed and the Saga of Xarelto and Pradaxa

Xarelto Cases Consolidated in New Orleans

Xarelto MDL Petition Filed Requesting Consolidation in the Southern District of Illinois

Xarelto Internal Bleeding Dangers on the Rise

 

Contact Us Today

Contact our lawyers directly through the email form below.
  • * Denotes a required field
  • This field is for validation purposes and should be left unchanged.